Compare VPG & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VPG | NMRA |
|---|---|---|
| Founded | 2009 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 479.2M | 424.4M |
| IPO Year | N/A | 2023 |
| Metric | VPG | NMRA |
|---|---|---|
| Price | $38.10 | $2.05 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 121.6K | ★ 980.8K |
| Earning Date | 11-04-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.60 | N/A |
| Revenue | ★ $299,283,000.00 | N/A |
| Revenue This Year | $0.48 | N/A |
| Revenue Next Year | $4.94 | N/A |
| P/E Ratio | $63.45 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $18.57 | $0.61 |
| 52 Week High | $39.86 | $11.57 |
| Indicator | VPG | NMRA |
|---|---|---|
| Relative Strength Index (RSI) | 61.07 | 39.73 |
| Support Level | $36.36 | $2.05 |
| Resistance Level | $39.20 | $2.36 |
| Average True Range (ATR) | 1.62 | 0.15 |
| MACD | 0.50 | -0.04 |
| Stochastic Oscillator | 82.08 | 15.32 |
Vishay Precision Group Inc manufactures and markets sensors, and sensor-based measurement systems, as well as specialty resistors and strain gages based on proprietary technology. The company provides precision products and solutions, many of which are designed-in by customers, specializing in the growing markets of stress, force, weight, pressure, and current measurements. The company reports in three product segments: Sensors segment, Weighing Solutions segment, and Measurement Systems segment. It has a business presence in the United States and other countries. It generates the maximum of its revenue from the United States.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.